A Study to Evaluate Treatment Patterns and Effectiveness of Luspatercept
← catalyst calendarSponsored by Bristol-Myers Squibb (industry) · BMY — their whole pipeline →.
Phase
—
Status
Active, not recruiting
Study type
Observational
Enrollment
430estimated
Sites
1
Country
United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2024-11-22 | actual | When the study began enrolling |
| Primary completion | 2025-08-01 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2025-08-01 | estimated | The whole study's end, after follow-up |
| First posted | 2025-05-14 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2025-05-14 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Myelodysplastic Syndromes (MDS)
Interventions
- Drug: Luspatercept
- Drug: Erythropoiesis-stimulating agent (ESA)
Primary outcomes
what the primary-completion date above is the date OFParticipant baseline demographics
measured Baseline
Luspatercept dose at treatment initiation
measured Baseline
Luspatercept dose at treatment discontinuation
measured Up to 50 months
Luspatercept dose change or escalation or reduction
measured Up to 50 months
Time from luspatercept initiation to the first occurrence of dose escalation
measured Up to 50 months
Proportion of participants that discontinued treatment
measured Up to 50 months
Time from treatment initiation to treatment discontinuation
measured Up to 50 months
Time from luspatercept/erythropoiesis stimulating agents treatment initiation to initiation of a new treatment for myelodysplastic syndromes
measured Up to 50 months
Permalink · BMY's whole pipeline · Catalyst calendar · Every registered study · What changed